

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Withdrawn) An L chain variable region (V region) of an antibody to human medulloblastoma cells, comprising three complementarity determining regions (CDRs) having the amino acid sequences defined below:

CDR1: Lys Ala ser Gin Asn Val Gly Thr Asn Val Ala

CDR2: Ser Ala Ser Tyr Arg Tyr Ser

CDR3: Gln Gln Tyr Asn Ser Tyr Pro Arg Ala

2.-39. (Cancelled)

F₁ 40. (Currently amended) A method for making a reshaped human antibody comprising:

(a) providing complementarity determining regions derived from a mouse antibody and framework regions derived from a human antibody,

(b) substituting an amino acid residue at position 46 of an L chain numbered according to Kabat is with a mouse antibody residue to provide ~~and the reshaped human antibody creates~~ a functional antigen binding site, and

(c) substituting 0-5 amino acid residue(s) on an H chain numbered according to Kabat with a mouse antigen binding site.

41. (Previously presented) The method of claim 40, wherein an amino acid residue 94 of H chain numbered according to Kabat et al. is an additional mouse antibody residue.

42. (Previously presented) The method of claim 41, wherein amino acid residues 27, 28, 29 and 30 of H chain numbered according to Kabat et al. are additional mouse antibody residues.

43. (Previously presented) The method of claim 40, wherein the amino acid residue 46 is proline.

44. (Withdrawn) A reshaped human antibody produced by the method of claim 40.

45. (Withdrawn) A reshaped human antibody produced by the method of claim 41.

46. (Withdrawn) A reshaped human antibody produced by the method of claim 42.

47. (Withdrawn) A reshaped human antibody produced by the method of claim 43.

48. (Currently amended) A method for making a single-chain Fv region comprising:

F. (a) producing a reshaped ~~human~~ antibody by substituting an amino acid residue ~~on~~ at position 46 of an L chain V region numbered according to Kabat, as a mouse antigen binding site and by substitution 0-5 amino acids on the H chain V region, numbered according to Kabat, with a mouse antigen binding site,

(b) linking the L chain V region and the H chain V region with a linker peptide, and

(c) combining identified complementarity determining regions derived from a mouse antibody and framework regions derived from a human antibody, wherein an amino acid residue 46 of L chain V region numbered according to Kabat is a mouse residue and the single chain Fv region creates a functional antigen binding site.

49. (Previously presented) The method of claim 48, wherein an amino acid residue 94 of H chain numbered according to Kabat et al. is an additional mouse antibody residue.

50. (Previously presented) The method of claim 49, wherein amino acid residues 27, 28, 29 and 30 of H chain numbered according to Kabat et al. are additional mouse antibody residues.

51. (Previously presented) The method of claim 48, wherein the amino acid residue 46 is proline.

52. (Previously presented) The method of claim 48, wherein the linker peptide has the following amino acid sequence:

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID NO: 111).

53. (Withdrawn) A single-chain Fv region produced by the method of claim 48.

54. (Withdrawn) A single-chain Fv region produced by the method of claim 49.

55. (Withdrawn) A single-chain Fv region produced by the method of claim 50.

56. (Withdrawn) A single-chain Fv region produced by the method of claim 51.

57. (Withdrawn) A single-chain Fv region produced by the method of claim 52.

58. (Previously presented) A method for making a reshaped human antibody comprising:

F₁
(a) providing complementary determining regions identified from a mouse antibody and framework regions identified from a human antibody, and

(b) substituting an amino acid residue of position 46 of an L chain numbered according to Kabat with a mouse antigen binding site and

(c) substituting 0-5 amino acid residue(s) on an H chain numbered according to Kabat with a mouse antigen binding site.

59. (Previously presented) A method for making a single-chain Fv region comprising:

(a) producing a reshaped antibody by substituting an amino acid residue on position 46 of an L chain V region numbered according to Kabat, with a mouse antigen binding site and by substitution 0-5 amino acids of an H chain V region numbered according to Kabat, with a mouse antigen binding site,

(b) linking the L chain V region and the H chain V region with a linker peptide, and

F₁
(c) combining identified complementary determining regions from a mouse antibody and framework regions identified from a human antibody, wherein an amino acid residue 46 of L chain V region numbered according to Kabat is a mouse residue and the single chain Fv region creates a functional antigen binding site.
